CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment

Détails

ID Serval
serval:BIB_5BD22996632F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment
Périodique
J Infect Dis
Auteur⸱e⸱s
Legrand E., Neau D., Galperine T., Trimoulet P., Moreau J. F., Pitard V., Lacut J. Y., Ragnaud J. M., Dupon M., Le Bail B., Bernard N., Schvoerer E., Houghton M., Fleury H., Lafon M. E.
ISSN
0022-1899 (Print)
ISSN-L
0022-1899
Statut éditorial
Publié
Date de publication
2002
Volume
186
Numéro
3
Pages
302-11
Langue
anglais
Notes
Legrand, Elisabeth
Neau, Didier
Galperine, Tatiana
Trimoulet, Pascale
Moreau, Jean-Francois
Pitard, Vincent
Lacut, Jean-Yves
Ragnaud, Jean-Marie
Dupon, Michel
Le Bail, Brigitte
Bernard, Noelle
Schvoerer, Evelyne
Houghton, Michael
Fleury, Herve
Lafon, Marie-Edith
eng
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
2002/07/23
J Infect Dis. 2002 Aug 1;186(3):302-11. doi: 10.1086/341659. Epub 2002 Jul 17.
Résumé
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens were evaluated before and during an anti-HCV regimen (interferon-alpha2a and ribavirin) in 36 patients coinfected with HCV and human immunodeficiency virus (HIV), to determine whether immune responses against HCV antigens are present in such patients, whether these responses are modified by anti-HCV treatment, and whether they are correlated with treatment efficacy. The CD4 responses against HCV antigens (primarily core antigens) detected at study entry in one-half of the patients did not correlate with anti-HCV treatment efficacy. Of 36 patients, 8 had patterns of persistent immune response to infection by genotypes 3 or 4 that were significantly correlated with sustained virologic response. Persistent immunologic reactivity and sustained virologic response coexisted only in patients infected with genotype 3. These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virologic control.
Mots-clé
Adult, Antiviral Agents/*pharmacology/standards/therapeutic use, CD4-Positive T-Lymphocytes/drug effects/*immunology, Female, HIV Core Protein p24/immunology, HIV Infections/complications/drug therapy/*immunology, HIV-1/*growth & development/immunology, Hepacivirus/*growth & development/immunology, Hepatitis C Antigens/blood/*immunology, Hepatitis C, Chronic/complications/drug therapy/*immunology, Humans, Interferon alpha-2, Interferon-alpha/standards/*therapeutic use, Lymphocyte Activation/drug effects/immunology, Male, Middle Aged, Recombinant Proteins, Ribavirin/standards/*therapeutic use, Statistics, Nonparametric, Tuberculin/immunology
Pubmed
Création de la notice
30/01/2023 12:16
Dernière modification de la notice
31/01/2023 7:55
Données d'usage